Britain and America have established a key trade agreement that will preserve zero duties on British drug products entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to increase expenditure on drugs through the public health system. This pledge secures that duties on these vital goods will be held at nothing for a period of three years.
This agreement is in response to earlier statements to dramatically increase tariffs on patented pharmaceutical products, with figures floated reaching 100%.
"This deal between the Britain bolsters the international landscape for new treatments and establishes much-needed equity to American-British pharmaceutical trade," an announcement noted.
Commercial Impact
Drugs constitute one of the UK's largest exports to the United States, which is by far the primary market for major UK drugmakers.
Export figures show that in the year leading up to the third quarter, the UK sold medicines valued at over eleven billion pounds to the US. This value accounted for nearly one-fifth of total UK exports in that period.
"This deal secures jobs, boosts investment and facilitates the UK to emerge as a worldwide center for biotech and pharma," a government official remarked.
Specific British Pledges
The pact entails several specific changes from the British government:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to raise total health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be capped at fifteen percent. In the past, refunds exceeded 20%.
Industry Background
The pact comes amid a ongoing tension between the drug companies and the ministers over drug pricing and regulatory access.
The disagreement were intensified by claims that American patients were paying significantly more for the equivalent treatments than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been halted or cancelled, while major investments have been announced toward projects in the United States.
A senior figure stated that the NHS must increase expenditure on treatments, noting that its budget allocation on drugs had decreased as a proportion of its total funding over the past decade.
